Zealand Pharma
Danish peptide specialist that co-develops petrelintide with Roche and licensed survodutide to Boehringer Ingelheim.
Share price
266 DKK
Down 36% over 12 monthsWhat analysts expect
Buy
Price target for the next 12 months
399 DKKUp 77% compared with the current price
Price now 226 DKKAverage targetLowest 290 DKK to highest 595 DKK
16 analysts. One bank cut its rating to Hold in October. Source: MarketScreener, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- 4.6B DKK
- Yearly profit
- 2.7B DKK
- Company value
- 19B DKK
- Forward P/E
- Not availableAs of 2026-10-22
- Forward P/S
- Not availableAs of 2026-10-22
Revenue and profit for the last twelve months reported.
Forward P/E compares the share price with forecast earnings per share. Forward P/S compares company value with forecast revenue. Both are dated estimates, separate from the live price. Missing or non-positive estimates are shown as unavailable.
Peptides in this book
- PetrelintideTrials only
- SurvodutideTrials only
Recent news
- 2026-10-08 Petrelintide gives up to 9.2 percent weight loss in mid-stage trial Reuters
Risk in the news: Reuters reported that shares fell about 20 percent over side-effect concerns in a Boehringer survodutide study.
Logo source: Zealand Pharma
Prices are delayed and figures rounded. Not investment advice.